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Abstract
Background: Several P-glycoprotein (P-gp) substrate tracers are available to assess P-
gp function in vivo, but attempts to develop a tracer for measuring expression levels of
P-gp have not been successful. Recently, (Z)-2-(5-fluoro-2-oxoindolin-3-ylidene)-N-(4-
methoxyphenyl)hydrazine-carbothioamide was described as a potential selective P-gp
inhibitor that is not transported by P-gp. Therefore, the purpose of this study was to
radiolabel two of its analogues and to assess their potential for imaging P-gp
expression using PET.
Results: [18F]2-(4-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-
carbothioamide ([18F]5) and [18F]2-(6-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)
hydrazine-carbothioamide ([18F]6) were synthesized and both their biodistribution and
metabolism were evaluated in rats. In addition, PET scans were acquired in rats before
and after tariquidar (P-gp inhibitor) administration as well as in P-gp knockout (KO) mice.
Both [18F]5 and [18F]6 were synthesized in 2–3% overall yield, and showed high brain
uptake in ex vivo biodistribution studies. [18F]6 appeared to be metabolically unstable in
vivo, while [18F]5 showed moderate stability with limited uptake of radiolabelled
metabolites in the brain. PET studies showed that transport of [18F]5 across the blood-
brain barrier was not altered by pre-treatment with the P-gp inhibitor tariquidar, and
uptake was significantly lower in P-gp KO than in wild-type animals and indeed
transported across the BBB or bound to P-gp in endothelial cells.
Conclusion: In conclusion, [18F]5 and [18F]6 were successfully and reproducibly
synthesized, albeit with low radiochemical yields. [18F]5 appears to be a radiotracer that
binds to P-gp, as showed in P-gp knock-out animals, but is not a substrate for P-gp.
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Background
The blood-brain barrier (BBB) is a tightly connected cell layer. Its main function is to
protect the brain from toxic substances by regulating their transfer between brain and
blood. Transfer across the BBB is possible either through passive diffusion or through
active influx and efflux (de Vries et al., 2005; Pike, 2009). One of the main proteins in-
volved in active efflux from the brain is P-glycoprotein (P-gp). P-gp is an
ATP-dependent 170–180 kDa transmembrane glycoprotein and, being located at the
luminal side of the BBB, it lowers brain concentrations of its substrates. P-gp is in-
volved in the transport of many small molecules from the brain back into the circula-
tion (de Vries et al., 2005; Pike, 2009) and, therefore, it plays a major role in the brain
pharmacokinetics of many drugs. In addition, changes in P-gp function are associated
with several diseases, such as HIV (Kim et al., 1998), depression (Szabo et al., 1999)
and temporal lobe epilepsy (Löscher & Sills, 2007; Luna-Tortos et al., 2008; Löscher &
Potschka, 2002).
The function of P-gp can be studied using positron emission tomography (PET)
(Luurtsema et al., 2010; Syvänen & Eriksson, 2013). To date, several PET tracers have
been developed based on known P-gp substrates to image cerebral P-gp function, such
as (R)-[11C]verapamil (Elsinga et al., 1996; Luurtsema et al., 2005) and [11C]desmethyl
loperamide (Zoghbi et al., 2008). Cerebral uptake of these substrate tracers is inversely
related to P-gp function. Although, subjects with decreased P-gp function show a
higher brain uptake of a substrate tracer, small but significant differences were observed
in practice (van Assema et al., 2012; van Assema et al., 2010). This is probably due to
the high capacity of P-gp and the relatively high noise levels associated with P-gp sub-
strate tracers, however the clinical relevance is limited by the small effects. In addition,
an increase in P-gp function, as proposed in pharmacoresistant epilepsy, is considerably
more difficult to assess using P-gp substrate tracers, as it requires quantification of a
decrease in tracer uptake from an already low level (Deo et al., 2014). In addition, Deo
et al. (Deo et al., 2014) showed that in AD patients it was difficult to detect reduced
P-gp function with (R)-[11C]verapamil, which was only successful when correcting K1
values for cerebral blood flow, illustrating the difficulties when using a substrate tracer
for measuring expression of P-gp. In addition van Assema et al. found a small increase
(R)-[11C]Verapamil BPND in the brain of patients with Alzheimer’s disease as compared
with values in healthy age-matched controls, which was however difficult to analyse
due to the low brain concentrations of (R)-[11C]Verapamil (van Assema et al., 2012).
An alternative approach to image P-gp upregulation with PET is the use of tracers,
which are weak to moderate P-gp substrates such as [11C]phenytoin (Verbeek et al.,
2012) and [11C]quinidine (Syvänen et al., 2013). These tracers show higher brain uptake
than [11C]verapamil (Verbeek et al., 2012) and, therefore, it may be easier to measure
reduced uptake as a result of P-gp upregulation. On the other hand, these tracers are
weaker substrates for P-gp and show less pronounced blocking effects.
P-gp substrates are low affinity inhibitors, e.g. quinidine will inhibit P-gp function at
sufficiently high doses. Under these conditions, most inhibitors would be expected to
be substrates at low concentrations as indeed observed for known P-gp inhibitors such
as [11C]laniquidar (Luurtsema et al., 2009), [11C]elacridar (Dorner et al., 2009) and
[11C]tariquidar (Bauer et al., 2010; Bankstahl et al., 2013). The signal obtained with
such a tracer should be, under ideal conditions (no unspecific binding for example),
Verbeek et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:11 Page 2 of 19
proportional to the level of P-gp expression and, therefore, upregulation of P-gp ex-
pression should result in an increased signal, which would be easier to measure (re-
duced noise levels). So far, however, these tracers have shown to be substrates at tracer
doses despite their known inhibitory nature at pharmacological doses as determined in
in vitro assays (Luurtsema et al., 2009). It has been postulated that, at these tracer
doses, the concentration of these compounds is too low to achieve full inhibition of
P-gp function, leading to transport of tracer and a picomolar affinity would be required
to measure P-gp expression (Kannan et al., 2013). This dose dependent behaviour has
been confirmed for [11C]laniquidar in experiments with variable amounts of
co-injected unlabelled laniquidar (Moerman et al., 2012). Clearly, this significantly
limits the usefulness of this class of P-gp tracers for studying upregulated P-gp expres-
sion, since the ideal tracer to delineate P-gp expression is an inhibitor that binds to the
protein but is not transported (Mullauer et al., 2013). On the other hand, if a P-gp in-
hibitor is not a substrate for P-gp at any dose, then a lower affinity would suffice.
Recently, in several in vitro assays, a large series of analogues of isatin thiosemicarba-
zides were identified as selective and potent compounds, which interact with P-gp (Hall
et al., 2009). Within this series, 2-(5-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphe-
nyl)hydrazine-carbothioamide was identified as an interesting lead compound for the
development of a PET tracer that would selectively interact to P-gp without being
transported, since its structure does not resemble any of the known P-gp inhibitors, it
might have different characteristics toward P-gp (Hall et al., 2009). This interaction
however, should be assessed in P-gp Knockout animals, whether this interaction is in-
deed towards P-gp. As the 5 position of the isatin moiety is not a suitable position for a
nucleophilic aromatic fluorination and with the 4 and 6 positions only slightly acti-
vated, the purpose of the present study was to develop the synthesis of two analogues,
[18F]2-(4-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-carbothioa-
mide ([18F]5) and [18F]2-(6-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)-hy-
drazinecarbothioamide ([18F]6), and to assess their potency as P-gp tracers in vivo in
rats and mice using both biodistribution and PET experiments.
Methods
General
Unless stated otherwise, chemicals were obtained from Sigma Aldrich (Zwijndrecht, the
Netherlands) and used without further purification. Acetonitrile, methanol, ethyl acetate
and hexane were purchased from Biosolve (Valkenswaard, the Netherlands), 4-nitroisatin
(4-nitro-2,3-dioxyindole) and 6-nitroisatin (6-nitro-2,3-dioxyindole) from Bio-Connect
BV (Huissen, the Netherlands), 4-(4-methoxyphenyl)-3-thiosemicarbazide (ABCR,
Giessen, Germany) and tariquidar from AzaTrius Pharmaceuticals Pvt. Ltd. (Mumbai,
India). [18F]F− was produced using an IBA Cyclone 18/9 cyclotron. Radiosyntheses were
performed using an in house built synthesis device (Windhorst et al., 2001).
Nuclear magnetic resonance (NMR) data were obtained using a Bruker AC 200
(Bruker, Billerica, USA) and chemical shifts (δ) were defined relative to the signal of the
solvent (7.27 for CHCl3, 2.50 for DMSO-d6). The following high performance liquid
chromatography (HPLC) methods were used: for preparative HPLC (method A) an
ACE 5 μM C18, 250*10 mm column (Alltech, Breda, the Netherlands) with
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acetonitrile/50 mM ammonium dihydrogenphosphate in water (pH = 4.7) 50/50 (v/v) as
eluent at a flow of 4 mL∙min− 1, UV monitoring at 254 nm and radioactivity detection
with an in house built radioactivity detector; for analytical HPLC (method B) a Kroma-
sil 100 C18 10 μM, 250*10 mm (Alltech, Breda, the Netherlands) with acetonitrile/
water/diisopropylamine 50/50/0.2 (v/v/v) as eluent at a flow of 1 mL∙min− 1, UV moni-
toring at 254 nm and a Raytest 2.5 in. NaI(Tl) radioactivity detector (Raytest, Strauben-
hardt, Germany); for metabolite analysis (method C) a Gemini C18, 5 μm 250*10 mm
(Phenomenex, Utrecht, the Netherlands) with the following gradient: A = acetonitrile
and B = 50 mM ammoniumacetate in water. T = 0 min: 0.25 mL·min− 1, T = 0.5 min:
6.00 mL·min− 1, T = 14.5 min: 6.00 mL·min− 1, T = 15.0 min: 0.25 mL·min− 1. Percentage
of B: T = 0 min: 60%, T = 10 min: 30%, T = 13 min: 30%, T = 13.5 min: 60% and T =
15 min: 60%, UV monitoring at 230 nm and radioactivity detection with an in house
built radioactivity detector.
Sprague-Dawley rats were obtained from Harlan (Horst, the Netherlands). Prior to
experiments, rats were housed in groups of 4 per cage. FVB (Friend virus B-type) P-gp
knockout (MDR1a/b (−/−)), FVB BCRP (Breast cancer restistant protein) knockout and
FVB wild type mice were obtained from Taconic (Hudson, USA). Animals were kept at
a constant temperature of 21 °C, a constant humidity of 50–60% and a 12 h light/dark
cycle, in which lights were switched on at 8:00 a.m. Animals had unrestricted access to
food (Teklad Global 16% Protein Rodent Diet, Harlan, Madison, WI, USA) and water.
All animal experiments were performed in compliance with the Dutch law on animal
experimentation. After a habituation period of approximately one week, PET, biodistri-
bution or metabolite studies were performed.
Synthesis of 4-fluoroisatin (3) and 6-fluoroisatin (4)
Both (3) and (4) were synthesized using the method of Zhang et al (Zhang et al., 2010).
12.8 g (89.6 mmol) Na2SO4 and 1.87 g (11.3 mmol) chloral hydrate were dissolved in
50 mL H2O at 35 °C. Next, a solution of 1.13 g (10.2 mmol) 3-fluoroaniline (1) in
15 mL H2O and 2 mL of 37% HCl in H2O was added, followed by the addition of
2.24 g (34.8 mmol) hydroxylamine hydrochloride in 20 mL water. This solution was
then heated to 90 °C for 2 h, and gently cooled to 50 °C over 1 h. The solution was
filtered and the filtrate was washed 3 times with 15 mL water, and subsequently the
filtrate was dried under vacuum to yield 1.41 g (7.8 mmol) 3- fluoroisonitroacetanilide
N-(3-fluorophenyl)-2-(hydroxyimino)acetamide (2) in 76%.
Next, 8 mL of concentrated H2SO4 was heated to 60 °C and 1.41 g (7.80 mmol) of (2)
was added portion wise to this solution during 45 min. The mixture was heated to 85 °C for
15 min and then cooled in an ice bath for 1 h. The mixture was poured into 35 mL water
and the precipitate was filtered off after 2 h. This precipitate was dissolved in 50 mL ethyl
acetate and washed 3 times with 40 mL H2O. The ethyl acetate layer was dried with
Na2SO4, filtered and the ethyl acetate was evaporated under vacuum to yield a mixture of
(3) and (4). Hereafter, both (3) and (4) were purified and separated using flash column
chromatography over silica, hexane/ethyl acetate 6/1, with an Rf of 0.25 for (3) and 0.15 for
(4), to yield a mixture of 0.063 g (0.38 mmol) of (3) 5% and 1.02 g (6.1 mmol) of (4) 79%.
(3): 1H-NMR (DMSO-d6) δ: 7.60 (1H, m, aromatic proton), 6.87 (1H, m, aromatic
proton), 6.74 (1H aromatic proton) 13C-NMR (DMSO-d6) 182.8, 169.5, 167.4, 160.1,
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153.8 d, 128.3 d, 115.3 d, 110.4 d, 110.2 d, 108.9, 100.7 d, and HRMS (ESI) m/z calcu-
lated for C8H5FNO2 (M
+) 166.0299 found 166.0308.
(4): 1H-NMR (DMSO-d6) δ: 7.62 (1H, M, aromatic proton), 6.84 (1H, t, aromatic
proton, J = 8 Hz), 6.72 (1H, d, aromatic proton, J = 8 Hz) 13C-NMR (DMSO-d6) δ:
180.4, 149.5, 159.2, 157.1, 151.8 d, 141.2 d, 110.4 d, 108.9, 106.5 d and HRMS (ESI) m/
z calculated for C8H5FNO2 (M
+) 166.0299 found 166.0307.
Synthesis of (Z)-2-(4-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-car-
bothioamide (5)
50 mg (0.30 mmol) of (3) was dissolved in 15 mL ethanol. To this solution 64 mg
(0.30 mmol) of 4-(4-methoxyphenyl)-3-thiosemicarbazide was added, as well as 20 μL
of acetic acid. This solution was heated to 110 °C in a closed reaction vessel for 2 h,
after which it was cooled to room temperature and left overnight so that (5) crystallized
out of the ethanol. The product was washed twice with 15 mL cooled ethanol (4 °C)
and dried under vacuum overnight to yield 59 mg (0.17 mmol) of (5) 57%.
(5): 1H-NMR (DMSO-d6) δ: 13.06 (1H, s, NH), 11.52 (1H, s, NH), 10.38 (1H, s, NH),
7.44–7.46 (3H, m, aromatic protons), 6.92–6.97 (3H, m, aromatic protons), 6.79 (1H, d,
aromatic proton J = 4 Hz), 3.77 (3H, s, OCH3)
13C-NMR (DMSO-d6) δ: 179.2, 165.1,
160.0, 158.0, 146.5 d, 135.9 d, 134.0, 133.2 t, 129.7, 116.2, 112.6, 112.5, 110.2 d, 109.8,
109.7 58.0 and HRMS (ESI) m/z calcd for C16H14FSN4O2 345.0816 (M
+) found 345.0787.
Synthesis of (Z)-2-(6-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-car-
bothioamide (6)
Starting with 50 mg (0.30 mmol) of (4), (6) was synthesized according to the same pro-
cedure as used for (5) to yield 69 mg (0.20 mmol) of (6) in 65% yield, and shown in Fig. 1.
(6): 1H-NMR (DMSO-d6) δ: 12.6 (1H, s, NH), 11.2 (1H, s, NH), 10.8 (1H, s, NH),
7.63 1H, m, aromatic proton), 7.46 (2H, d, aromatic protons, J = 8 Hz), 7.20 (1H, m,
Fig. 1 Reaction conditions: i: Na2SO4, chloral hydrate, H2O, HCl, hydroxylamine hydrochloride 90 °C 2 h; ii
H2SO4 85 °C 15 min; iii ethanol 110 °C 2 h
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aromatic proton) 6.98 (2H, d, aromatic protons, J = 8 Hz), 6.94, (1H, m, aromatic pro-
ton), 3.79 (3H, s, OCH3),
13C-NMR (DMSO-d6) δ: 179.2, 165.5, 161.9, 160.1, 160.0,
141.4, 134.1 d, 133.8, 129.9, 124.1 d, 120.2 d, 116.3, 114.8 d, 110.9 d, 58.0 and HRMS
(ESI) m/z calculated for C16H14FN4O2 345.0816 (M
+) found 345.0791.
Radiosynthesis
[18F]5 was synthesized starting from 15 to 74 GBq [18F]F− in a mixture of 1 mL, 9/1 (v/v)
acetonitrile/water, containing 13 mg (34.5 μmol) of kryptofix and 2 mg (14.5 μmol) of
potassium carbonate. This mixture was dried under vacuum at 90 °C for 6 min, while
passing a helium flow (50 mL·min− 1) over the solution. This was repeated with 1 mL of
dry acetonitrile. Next, 0.5 mL of dry DMSO containing 4.6 mg (24 μmol) of 4- or
6-nitroisatin was added and the mixture was heated at 140 °C for 40 min. Then, 4.5 mL of
water was added and the total was passed over a Waters tC-18 plus Sep-Pak, pre-treated
with 5 mL of ethanol, followed by 5 mL of water. The Sep-Pak was rinsed with 10 mL of
water and, using 1.5 mL of ethanol (98%), [18F]3 was eluted from the Sep-Pak to a second
reaction vial, which already contained 9 mg (42 μmol) of 4-(4-methoxyphenyl)-3-thiose-
micarbazide. Next, 50 μL of acetic acid was added and the mixture was heated at 120 °C
for 30 min. The solution was cooled to room temperature and quenched with 1.5 mL of
water. This mixture was loaded onto HPLC and purified (method A). The product, [18F]5
was eluted at 20 min and collected within 1 min. This fraction was diluted with 16 mL of
water and passed over a Waters C18 light Sep-Pak cartridge, pre-treated with 5 mL of
ethanol followed by 5 mL of water. Next, this cartridge was washed with 10 mL of water
and reversely eluted with 2 mL of water containing 20 mass% Tween-80. The eluate was
diluted with 2 mL of sterile saline and the total solution was passed over a Millex GV filter
(Millipore, Amsterdam, the Netherlands). The radiochemical purity was determined by
HPLC method B.
[18F]6 was synthesized using exactly the same procedure as described for [18F]5, except that
6-nitroisatin was used instead of 4-nitroisatin as precursor for the radiosynthesis of [18F]6.
Biodistribution
Biodistribution of both [18F]5 (8.6 ± 1.8 MBq, mean ± SD) and [18F]6 (6.8 ± 0.6 MBq) in
Sprague-Dawley rats (N = 4 for both compounds) was determined at 10 and 45 min
after injection. Animals were injected in a tail vein under isoflurane anaesthesia and
euthanized at one of the two time points, again under isoflurane anaesthesia. Heart,
lungs, liver, kidneys, testes and bone were dissected, and blood and urine were
collected. In addition, olfactory bulb, hippocampus, striatum, cerebral cortex,
cerebellum and remaining parts of the brain were dissected. All tissues were counted
for radioactivity using a gamma counter (LKB Wallac, Turku, Finland) and weighed.
Results were expressed standard uptake value (SUV).
Metabolite analysis
Metabolic profiles of both radiotracers in both plasma and brain were assessed in
Sprague-Dawley rats, at 10 and 45 min after injection of the radiotracer (2 animals per
time point). Blood (2 mL) was collected and half the brain was isolated during the
biodistribution experiments, as described in the biodistribution section.
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Blood was collected in heparin tubes and subsequently plasma was separated from cells
by centrifugation for 5 min at 4000 rpm (Hettich universal 16, Depex B.V., Houten, the
Netherlands). Thereafter, plasma was loaded onto a tC18 Sep-Pak (Waters, Etten-Leur,
the Netherlands), washed with 3 mL of water, and the eluate was considered to be the
radiolabelled polar metabolite fraction, which was confirmed using HPLC method C.
Next, the Sep-Pak was eluted with 2 mL of methanol to obtain the radiolabelled
non-polar metabolite fraction. This fraction was analysed using HPLC method C.
Brain tissue was homogenised using an ultrasonic homogenizer (Braunsonic 1510,
Germany) in water, under ice cooling, and subsequently centrifuged at 4000 rpm for
5 min. Separated supernatants were loaded onto a tC18 Sep-Pak, washed with 3 mL
water to obtain the polar fraction and subsequently washed with 2 mL methanol to
obtain the non-polar fraction, which again was analysed using HPLC method C.
PET studies
Animals were anaesthetized via a nose mask with 4 and 2% isoflurane in oxygen for in-
duction and maintenance, respectively, at a rate of 1 L·min− 1. One hour prior to each
study, a femoral vein and a femoral artery were cannulated for administration of radio-
tracer and tariquidar, and for blood sampling, respectively. In mice no blood sampling
was performed. Blood oxygen saturation and body temperature were monitored con-
tinuously throughout surgery and experiments. Heating and oxygen supply were ad-
justed to maintain a body temperature of ~ 36 °C and an oxygen saturation > 96%.
Rats were positioned in pairs, while mice were scanned in groups of 5 using a double
LSO/LYSO layer High Resolution Research Tomograph (HRRT; Siemens/CTI, Knox-
ville, TN, USA) (Zhang et al., 2010). First, for attenuation and scatter correction pur-
poses, a transmission scan was acquired using a 740 MBq 2-dimensional (2D)
fan-collimated 137Cs (662 keV) moving point source (van Velden et al., 2008; de Jong et
al., 2007).
Immediately after the transmission scan, [18F]5 (6.3 ± 0.7 MBq (350–400 μL) for rats,
2.2 ± 0.3 MBq (120–150 μL) for mice was administered and a dynamic emission scan of
60 min was started. In the case of rat studies, blood samples were withdrawn at ten
time points during the scan, weighed and counted for amount of radioactivity. At the
end of this emission scan, for both rats and mice [18F]NaF (3.6 ± 0.4 MBq) was injected
and a second emission scan was initiated (30 min). This last scan was used for
co-registration with an MR based rat brain atlas (Buiter et al., 2012), while for the mice
study the co-registration of the brain was performed manually using the [18F]NaF scan
as a reference for the skull as shown in Scheme 1.
After the [18F]NaF scan, both cannulation lines were filled with a mixture of Polyvi-
nylpyrrolidonum / heparin in saline and closed. Next, animals were allowed to recover
from anaesthesia and kept overnight with free access to food and water. The following
day, rats were treated with 15 mg/kg tariquidar (Bankstahl & Lösscher, 2008) iv, 15 min
prior to an identical imaging procedure. On the second day the dose of [18F]5 was 6.8
± 0.3 MBq and the dose of [18F]NaF 4.9 ± 0.3 MBq.
Because [18F]5 and [18F]6 were formulated in a 10% tween-80 containing solution, its
effect on P-gp function was also investigated. In a separate group of rats (N = 4)
(R)-[11C]verapamil data were obtained. After a transmission scan, a dynamic emission
Verbeek et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:11 Page 7 of 19
scan (60 min) was acquired immediately following administration of (R)-[11C]verapamil
(11.3 ± 1.2 MBq) (450-500 μl) formulated in 10 mass% of Tween-80. After the baseline
scan, animals were treated with 15 mg/kg tariquidar iv. Fifteen minutes after tariquidar
administration,).: a second emission scan was acquired after injection of (R)-[11C]vera-
pamil (6.4 ± 2.5 MBq) formulated in 10 mass% of Tween-80 scan, followed by a third
30-min emission scan was acquired after injection of [18F]NaF (6.0 ± 0.5 MBq).
List mode data of both acquired [18F]5 and (R)-[11C]verapamil scans were rebinned
into the following frame sequence: 7 × 10, 1 × 20, 3 × 30, 2 × 60, 2 × 150, 2 × 300 and
4 × 600 s. The [18F]NaF scan was rebinned into a single 1800 s frame. Following
normalization of the data and corrections for decay, dead time, attenuation, randoms
and scatter, scans were reconstructed using 3D ordinary Poisson ordered subsets ex-
pectation maximization. This resulted in images with an average spatial resolution of
2.5 mm full width at half maximum (van Velden et al., 2009).
Image data were analysed using the freely available software package Amide 0.9
(Loening & Gambhir, 2003). An MR based rat brain atlas was used to define a whole
brain region of interest. For each rat, the MR atlas was aligned visually with the
[18F]NaF image using a procedure described previously (Buiter et al., 2012).
Results
Chemistry
(3) and (4) were synthesized in overall yields of 4 and 60%, respectively, whilst the last
synthesis steps of the reference compounds for (5) and (6) were obtained with yields of
57 and 65%, respectively. This led to an overall synthesis yield of 2.1% for (5) and 39%
for (6). After purification, both reference compounds (5) and (6) showed no impurities
and they were analysed using proton and carbon NMR. Exact masses were found to be
345.0787 for (5) and 345.0791 for compound (6).
Radiosynthesis
Radiosynthesis of [18F]3 was optimized according to Table 1. The highest yields were
obtained when performing the reaction in DMSO at 140 °C for 40 min with 24 μmol of
4-nitroisatin.These optimized conditions were also used for the synthesis of [18F]4. The
reaction scheme is shown in Fig. 2.
Using a waters tC18 plus Sep-Pak it was possible to trap all [18F]3 and, after elution
with 1.5 mL ethanol, less than 1% of the total radioactivity remained on the cartridge.
The yield of the second step was optimized to 35–50% using 9 mg (42 μmol) of
[
18
F]5 [
18
F]NaF 
Scheme 1 showing 5 min. Transmission scan, followed by injection of [18F]5 during a 60 min scan, after
which a second transmission scan was performed. Next [18F]NaF was injected during a 30 min. Scan
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4-(4-methoxyphenyl)-3-thiosemicarbazide at 120 °C for 30 min in ethanol. The same
reaction conditions were used in the radiosynthesis of [18F]6.
Formulation of the final product was performed with a Waters tC-18 light Sep-Pak.
After dilution with water, the product was trapped, washed with 10 mL of water and
then eluted with 2 mL of 20 mass% Tween-80 in water. Approximately 10–20% of the
radioactivity remained on the Sep-Pak. After dilution with 2 mL water, the product was
passed over a Millex GV sterile filter, yielding 2.1 ± 0.9% of [18F]5 (N = 7) or 2.3 ± 1.0%
of [18F]6 (N = 6), both corrected for decay and with a specific activity of 91 ±
23 GBq·μmol− 1 for [18F]5, and 97 ± 25 for [18F]6 at end of synthesis.
Both [18F]5 and [18F]6 did not appear to be stable in either ethanol or saline (Table 2),
Moreover, addition of gentisic acid or ascorbic acid as radical scavengers were also
tested to enhance the stability in the product vial. Using DMSO instead of ethanol did
not result in a stable product either. Both [18F]5 and [18F]6 were stable within a range
of 10% -100% acetonitrile in water (not shown in Table 2), as well as in a solution of
2.5% and 20% Tween-80 in saline and without the use of ethanol.
Biodistribution
As shown in Fig. 3 the concentration of radioactivity in blood remained relatively high
with SUV values at 45 min of about 2 and 3 for [18F]5 and [18F]6, respectively. The
amount of activity in peripheral organs was relatively low with the highest uptake in
the liver with an SUV at 10 min of 3.9 and 5.2 for [18F]5 and [18F]6, respectively.
Uptake in the testes was relatively low (SUV between 0.2 and 0.3 for [18F]5 and [18F]6,
respectively), being rather stable between 10 and 45 min after injection. Bone uptake of
both tracers appeared to decrease slowly over time. All brain areas showed high uptake
of both tracers together with moderate washout. The highest uptake in the brain was
Table 1 Optimization of reaction conditions for radiosynthesis of [18F]3
Solvent 0.5 mL Precursor
(μmol)
Temperature
(°C)
Kryptofix
(μmol)
K2CO3
(μmol)
Yield
(%)
DMSO 26 120 6 3 6%
DMSO 24 140 6 3 7%
DMSO 54 140 6 3 5%
DMSO 26 160 6 3 4%
MeCN 26 140 6 3 1%
MeCN 24 140 18 9 2%
DMSO 16 140 6 3 3%
Fig. 2 reaction conditions: (i) DMSO, [18F]fluoride, Kryptofix[2.2.2], K2CO3, 40 min. 140 °C (5–6% yield) (ii)
ethanol, acetic acid, 30 min. 120 °C (35–50% yield)
Verbeek et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:11 Page 9 of 19
seen in olfactory bulb, hippocampus and striatum, whilst cerebral cortex, cerebellum
and remaining parts of the brain showed lower brain uptake (Fig. 3).
Metabolite analysis
Metabolite analysis, performed in Sprague Dawley rats (N = 2 for each tracer), showed
rapid metabolism of both tracers, especially for [18F]6 (Table 3). As early as 10 min
after injection, most of the radioactivity in plasma was due to radiolabelled metabolites.
For [18F]6, high levels of radiolabelled metabolites (~ 80%) in the brain were detected.
The level of radiolabelled metabolites in the brain was lower for [18F]5. At 45 min after
injection, 68% of the radioactivity in the brain was in the form of intact [18F]5.
In the brain, only one main metabolite was observed for both [18F]5 and [18F]6. A
representative HPLC chromatogram of [18F]5 is shown in Fig. 4, indicating an unidenti-
fied metabolite eluting 2 min before [18F]5. In plasma, however, metabolites were
mainly found in the polar fraction, although the brain metabolite was also observed.
Table 2 Stability of [18F]5 assessed in several formulation solutions; N = 2 for each time point
Time (Minutes) 5 15 30 45 60 90
10% ethanol in saline 92 – – – 76 69
DMSO 89 85 – – 72 –
Ethanol 97 80 – 67 – –
Free radical scavengers 95 – 89 – 79 –
acetonitrile 96 – 96 – 96 –
20% Tween-80 in saline 95 95 – 95 – –
2.5% Tween-80 in saline 95 94 94 94 94 –
Fig. 3 Biodistribution of [18F]5 and [18F]6 in Sprague-Dawley rats (N = 4) at 10 and 45 min after injection
depicted in SUV
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PET studies
Effect of Tween-80 on uptake of (R)-[11C]verapamil
Since both [18F]5 and [18F]6 were formulated in a solution containing 10% tween-80, the
effect of 10% Tween-80 on cerebral uptake of (R)-[11C]verapamil was investigated. In
Fig. 5, uptake of (R)-[11C]verapamil formulated with 10% Tween 80 (N = 4) is shown both
before and after treatment with 15 mg/kg tariquidar. For comparison, previous data by
Syvänen et al (Bankstahl & Lösscher, 2008), in which (R)-[11C]verapamil was formulated
in 10% ethanol, are also included. For both naïve and treated animals, 10% Tween-80 for-
mulated (R)-[11C]verapamil showed a slightly higher, although insignificantly initial uptake
of (R)-[11C]verapamil in the brain followed by faster clearance from the brain.
[18F]5 uptake before and after tariquidar treatment
Whole brain time activity curves of [18F]5 (N = 4) are shown in Fig. 6. Maximum SUV
was, on average, 2.2 at 5 min, followed by slow washout to a level of 0.8 after 45 min.
Both brain and blood concentrations increased after tariquidar treatment. Brain SUV
increased to about 3.0 and 1.5 at 5 and 45 min, respectively, whilst blood concentra-
tions increased by a factor of 1.5 ± 0.2 after 45 min. As a first order correction for
Table 3 Percentage of intact tracer in plasma and brain after 10 and 45 min (N = 2)
% intact [18F]5 % intact [18F]6
10 min
Plasma 21.5 ± 0.7 14.0 ± 2.8
Brain 62.5 ± 6.4 20.5 ± 0.7
45 min
Plasma 11.5 ± 2.1 7.0 ± 0.0
Brain 68.5 ± 2.1 16.0 ± 0.7
Fig. 4 A representative HPLC chromatogram (method C) of the non-polar fraction of the brain
homogenate at 10 min after injection, showing both [18F]5 (Rt 11 min) and a labelled metabolite (Rt 9 min)
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increased delivery the ratio of brain SUV to whole blood SUV was calculated. This ratio
was not significantly different between baseline and tariquidar pretreated scans (Fig. 7).
[18F]5 uptake in WT, P-gp and BCRP knockout mice
PET studies were performed in both P-gp and BCRP knockout mice, and results were
compared with those in wild-type mice. Ten minutes after injection, brain SUV of [18F]5
was 1.3 ± 0.1 (N = 4), 1.9 ± 0.2 (N = 5) and 1.9 ± 0.1 (N = 5) for P-gp knockout, BCRP
knockout and wild type mice, respectively. A summed PET image (2–20 min) of [18F]5 in
a WT mouse and a P-gp KO mouse is shown (Fig. 8). A significant reduction in brain up-
take compared with wild type mice, with a P < 0.05 was observed between 5 and 28 min,
differences in uptake between mice lost its significance at later time points (Fig. 9).
Fig. 5 Cerebral uptake of (R)-[11C]verapamil in naïve and 15 mg/kg tariquidar pre-treated rats, both with
and without formulation in 10% Tween-80; data without 10% Tween-80 were derived from Syvänen et al
(Syvänen et al., 2011)
Fig. 6 Whole brain time activity curves of [18F]5 before (blue diamonds) and after (red squares) 15 mg/kg
tariquidar (a specific P-gp inhibitor) treatment
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Because of the low blood volume of mice, no blood samples were withdrawn. In
addition, no image derived input function could be obtained due to the relatively low
resolution of the HRRT scanner in comparison with the size of the mouse heart. To as-
sess whether there were any differences in delivery between groups, uptake in muscle
was also measured. The muscle uptake in Fig. 10 shows the uptake of [18F]5 depicted
in SUV in the 2 KO mice compared to the WT mice, and the uptake appears to be
similar for all three strains, thus indicating that there are no differences in blood con-
centration, since the uptake is mainly dependent on influx of blood flow.
Discussion
2-(5-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-carbothioamide
was, despite its micromolar IC50, identified as an interesting lead for the development
Fig. 7 Brain to blood concentration ratio of [18F]5 before (blue diamonds) and after (red squares)
15 mg/kg tariquidar
Fig. 8 Summed PET image (2–20 min) of [18F]5 in a wild-type mouse (left) and a P-gp KO mouse (right)
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of an F-18 labelled PET ligand, which would selectively bind to P-gp without being
transported (Hall et al., 2009). Unfortunately, it was not possible to synthesize
[18F]5-fluoroisatin, presumably due to the position of the leaving group on isatin that
cannot be properly activated to allow for a nucleophilic aromatic substitution reaction
with [18F]fluoride. Hall et al. (Hall et al., 2009), however, have shown that modifications
at this part of the isatin moiety are allowed without significantly affecting the inhibitory
potency towards P-gp. Therefore, it was assumed that altering the structure by introdu-
cing an F-18 label at either the 4 or 6 position of isatin, would only have a minor effect
on its inhibitory potency. In addition, in vitro assays have shown limited predictive
value for P-gp binding at tracer levels and, therefore, the affinity for P-gp was assessed
directly in a knockout animal model.
4-Fluoroisatin 3 and 6-fluoroisatin 4 were synthesized in an overall yield of 4 and 60%,
respectively. These yields were slightly lower than those reported by Zhang et al (Zhang
et al., 2010), which may be due to the small scale synthesis performed in the present study
Fig. 9 Whole brain time activity curves of [18F]5 in P-gp KO mice (red squares), BCRP KO mice (blue
diamonds) and WT mice (green triangles)
Fig. 10 Muscle time activity curves of [18F]5 in P-gp KO mice (red squares), BCRP KO mice (blue diamonds)
and WT mice (green triangles)
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as crystallization usually performs better at a larger scale. The synthesis yields of the two
isatin-β-thiosemicarbozones were also comparable with those reported previously (Hall et
al., 2009) for the 5-fluoro isomer. This led to an overall synthesis yield of 2.1% for
(Z)-2-(4-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecarbothioamide 5
and 39% for (Z)-2-(6-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecar-
bothioamide 6, which was sufficient for synthesis of the reference compounds.
The first step in the radiosynthesis of [18F]3 was optimized by varying several param-
eters, such as amount of precursor, time, temperature and solvent. This led to an opti-
mized radiochemical yield of 5–7%, which makes this step the limiting step regarding
the overall yield, these optimized conditions were also used for the synthesis of [18F]4.
This low yield can be expected based on the poorly activated labelling positions on the
aromatic ring of both 4-nitroisatin and 6-nitroisatin.
Radiosyntheses of [18F]5 and [18F]6, starting from [18F]3 and [18F]4, respectively, were
optimized by changing temperature and reaction time to obtain a yield of 35–50% in
1.5 mL of ethanol, 50 μL acetic acid, and 9 mg (42 μmol) of 4-(4-methoxyphenyl)-3-thio-
semicarbazide for 30 min at 120 °C in a closed reaction vial. Reducing reaction time or
amount of the carbazide, or changing the reaction temperature led to lower yields. Both
acetonitrile and DMSO were also considered as solvent, but this led to a decrease in yield.
The large amount of 4-(4-methoxyphenyl)-3-thiosemicarbazide was required due to the
fact that unreacted nitroisatin precursor could not be separated from [18F]3 by the
Sep-Pak procedure. Consequently, 26 μmol nitroisatin was still present during the second
reaction, which also reacted with 4-(4-methoxyphenyl)-3-thiosemicarbazide.
Both [18F]5 and [18F]6 did not appear to be stable in either ethanol or saline (Fig. 3),
which is a major drawback for future applications, since most PET tracers are reformu-
lated in concentrations of up to 10% of ethanol in saline of buffer. Moreover, addition
of gentisic acid or ascorbic acid as radical scavengers (Table 2), did not improve stabil-
ity of the formulated product. Which is indicating that radical formation might not be
the cause of the instability of [18F]5 and [18F]6. Both [18F]5 and [18F]6 were stable
within a range of 10% -100% acetonitrile in water, but these amounts of acetonitrile
cannot be tolerated for iv injection. Finally, after assessing the formulation solution
within a range of 2.5% - 20% Tween-80 in water and without using ethanol, both [18F]5
and [18F]6 were stable over time. A solution of up to 10% Tween-80 can be used in ani-
mal studies (Li & Zhao, 2007). As an alternative to the Sep-Pak method, evaporation
was performed by passing a flow of helium gas through the solution at room
temperature, but this procedure led to decomposition of the radiotracers, which in turn
led to the conclusion that a Sep-Pak procedure was required, and thus the ethanol, to
reformulate both [18F]5 and [18F]6.
Although the yield of the formulated product was quite low (2% to 3%), the synthesis
was reliable and produced adequate amounts of product for biological evaluation. No
failures were observed during 16 syntheses.
Biodistributions of [18F]5 or [18F]6 were assessed in Sprague-Dawley rats at 10 min
(N = 4) and 45 min (N = 4) after radiotracer injection. At 45 min, radioactivity levels in
blood remained relatively high for both tracers. In contrast, radioactivity in peripheral
organs was relatively low, indicating fast washout. As bone uptake of both [18F]5 and
[18F]6 was low and even decreased over time, defluorination of the tracers seems un-
likely and PET measurements of cerebral uptake will not be confounded by high uptake
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in the skull. Baseline uptake in the testes (0.15% ID/g) was also increased compared
with (R)-[11C]verapamil (Elsinga et al., 1996; Luurtsema et al., 2005) and [11C]tariquidar
(Bauer et al., 2010), where the amount of activity in the testes remained below 0.3% ID/
g. This is an indication of binding to P-gp in the blood-testes barrier as well. Both
[18F]5 and [18F]6showed high uptake in the brain with moderate washout.
Metabolism of both radiotracers was fast, especially that of [18F]6, which showed only
20% of intact compound in the brain already at 10 min. Metabolically, compound
[18F]5 was more stable with 63% intact tracer in the brain at 10 min. Based on the
lower level of radiolabelled metabolites in the brain, [18F]5 was pursued in in vivo ani-
mal studies, although 30–40% of metabolite fraction in the brain still is rather high.
Since both [18F]5 and [18F]6 were formulated in a 10% Tween-80 solution, it was ne-
cessary to assess the effects of Tween-80 on P-gp function. Therefore, PET data were
acquired using (R)-[11C]verapamil, formulated in 10% Tween-80 in saline, comparing
results with previously acquired PET data using (R)-[11C]verapamil formulated in 10%
ethanol in saline, as reported by Syvänen et al. (Syvänen et al., 2011). As can be seen in
Figs. 5, 10% Tween-80 only had a minor effect on final [11C]verapamil uptake, although
initial brain uptake appeared a little higher in the first 5 min after injection.
In order to assess whether [18F]5 is a P-gp substrate, a blocking study was performed
using 15 mg/kg tariquidar, which is sufficient to completely block P-gp function (Syvä-
nen et al., 2011). In the blocking study, a 20% increase in [18F]5 uptake in the brain
was observed. At the same time, however, radioactivity levels in whole blood also in-
creased. Therefore, the ratio of brain SUV to blood SUV was used as a first order cor-
rection for increased delivery of [18F]5 to the brain following tariquidar treatment. As
shown in Fig. 9, the increased brain uptake could be explained entirely by increased de-
livery of [18F]5. This in turn was likely due to a blocking effect on peripheral binding
sites. For comparison, brain uptake for the substrate tracer (R)-[11C]verapamil in-
creased 10-fold following tariquidar treatment (Loening & Gambhir, 2003). In contrast,
for [18F]5, it only increased by 30% (not corrected for blood input). These findings sug-
gests that [18F]5 is not a substrate for P-gp, and perhaps binds on or interacts with a
different binding site, this however, should be further studied.
PET studies of P-gp knockout mice showed a significant reduction in brain uptake
compared with wild type mice, with a P < 0.05 between 5 and 28 min thus supporting
the observation that [18F]5 binds to P-gp. At late times, time activity curves were not
significantly different between knockout and wild type mice, most likely due to the
large metabolite fraction. The uptake in the early time points confirm the in vitro find-
ings by Hall et al (Hall et al., 2009), indicating that the 5-fluoro analogue is a selective
inhibitor of P-gp. Given these results, it seems very likely that [18F]5 binds to P-gp, but
is not a substrate for P-gp. Since pre-treatment with tariquidar gave similar PET results
compared to baseline it is likely that [18F]5 binds to a different binding site of P-gp than
tariquidar or that an higher specific activity of [18F]5 would be required, since the dose
administered was in the range of 1.0 ± 0.2 pmol/gram. Further studies, such as metabol-
ite analysis in knock out animals, are required to investigate this hypothesis in-depth.
Due to the limited blood volume of mice, blood concentrations in mice where not
measured during the scanning procedure. Therefore, uptake in muscle was assessed
and, as shown in Fig. 10, there were no significant differences observed between the
different groups of animals. As there are no known binding sites in muscle, the
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similarity in muscle uptake between groups suggests that there are no significant differ-
ences in delivery. This, in turn, indicates that the differences in brain uptake between
the different groups are due to differences in P-gp expression and not due to differ-
ences in delivery.
Finally, BCRP knockout mice showed no significant differences in brain uptake com-
pared with wild type mice, indicating that [18F]5 is neither binding nor being trans-
ported by BCRP in contrast to [11C]Elacridar for example (Bankstahl et al., 2013).
Further (in vitro) studies are required to validate this compound as a P-gp expression
tracer, for example performing the PET experiment in P-g knockout rats, which allow
for blood sampling and metabolite analysis during the PET scan, which would also
allow for reliable kinetic modelling. In addition a self-block, or an evaluation of com-
pound [18F]5 in the tumour models described by Hall et al (Hall et al., 2009), might
provide some extra additional information about the potency of compound [18F]5, this
is however beyond the scope of the initial preclinical evaluation of [18F]5, which ap-
pears to be an interesting lead.
Conclusion
Both [18F]5 or [18F]6 were successfully and reproducibly synthesized. Especially [18F]6
showed fast metabolism. [18F]5 appears to be a radiotracer that binds to P-gp, as showed
in P-gp knock-out animals, but is not a substrate for P-gp. Therefore, it is a promising
tracer for assessing P-gp expression levels in vivo, which however needs to be further
investigated.
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